Study

EORTC-26091-TAVAREC

Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas: The TAVAREC trial.

Study documentation Back to result

Trial Status

All trial activities ended

Dates

Date of activation: 02-Feb-2011
Date Step1 close: 31-Jul-2015

Data management at EORTC

Yes

Design

Phase 2
Randomized open label

Targeted Sample size

EORTC Groups: 144 - All Groups: 144

Protocol summary

http://clinicaltrials.gov/study/NCT01164189

NCT number

NCT01164189

EudraCT

2009-017422-39

Study

EORTC-26091-TAVAREC

Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas: The TAVAREC trial.

Study documentation Back to result

Research Projects

RP-1626

Predictors of quality of life ratings from patients with primary brain tumors: the role of self-awareness and cognitive functioning